<?xml version="1.0" encoding="UTF-8"?>
<p>Antiviral drugs are used to treat patients with strongly suspected or confirmed influenza. However, until a vaccine is available, specific protection by pharmaceutical products is limited to antiviral drugs. Nonpharmaceutical interventions are also available for prevention. Some governments and organizations are taking steps that would enable mass administration of these drugs (
 <xref ref-type="bibr" rid="R2">
  <italic>2</italic>
 </xref>). This administration may prove problematic. A recent study showed that schoolchildren may incompletely adhere to oseltamivir prophylaxis instructions (
 <xref ref-type="bibr" rid="R3">
  <italic>3</italic>
 </xref>). If other groups are given oseltamivir prophylaxis, they cannot necessarily be expected to follow administration guidelines; compliance with taking the recommended number of doses at appropriate times is difficult to enforce. Moreover, even when compliance is high, oseltamivir prophylaxis may fail (
 <xref ref-type="bibr" rid="R4">
  <italic>4</italic>
 </xref>).
</p>
